GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (STU:1FG) » Definitions » Cyclically Adjusted PS Ratio

FibroGen (STU:1FG) Cyclically Adjusted PS Ratio : 0.39 (As of Jun. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Cyclically Adjusted PS Ratio?

As of today (2024-06-16), FibroGen's current share price is €1.062. FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €2.70. FibroGen's Cyclically Adjusted PS Ratio for today is 0.39.

The historical rank and industry rank for FibroGen's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:1FG' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.14   Med: 0.66   Max: 8.47
Current: 0.4

During the past years, FibroGen's highest Cyclically Adjusted PS Ratio was 8.47. The lowest was 0.14. And the median was 0.66.

STU:1FG's Cyclically Adjusted PS Ratio is ranked better than
92.06% of 504 companies
in the Biotechnology industry
Industry Median: 5.38 vs STU:1FG: 0.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

FibroGen's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.520. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.70 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for FibroGen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted PS Ratio Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 5.52 0.32

FibroGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.40 0.93 0.31 0.32 0.83

Competitive Comparison of FibroGen's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted PS Ratio falls into.



FibroGen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

FibroGen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.062/2.7
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, FibroGen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.52/131.7762*131.7762
=0.520

Current CPI (Mar. 2024) = 131.7762.

FibroGen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.401 100.560 1.836
201409 0.190 100.428 0.249
201412 0.221 99.070 0.294
201503 0.254 99.621 0.336
201506 1.562 100.684 2.044
201509 0.286 100.392 0.375
201512 0.364 99.792 0.481
201603 0.408 100.470 0.535
201606 1.151 101.688 1.492
201609 0.427 101.861 0.552
201612 0.532 101.863 0.688
201703 0.430 102.862 0.551
201706 0.387 103.349 0.493
201709 0.448 104.136 0.567
201712 0.316 104.011 0.400
201803 0.312 105.290 0.390
201806 0.449 106.317 0.557
201809 0.294 106.507 0.364
201812 1.116 105.998 1.387
201903 0.246 107.251 0.302
201906 1.848 108.070 2.253
201909 0.346 108.329 0.421
201912 0.082 108.420 0.100
202003 0.250 108.902 0.303
202006 0.426 108.767 0.516
202009 0.399 109.815 0.479
202012 0.586 109.897 0.703
202103 0.352 111.754 0.415
202106 0.219 114.631 0.252
202109 1.429 115.734 1.627
202112 0.158 117.630 0.177
202203 0.594 121.301 0.645
202206 0.302 125.017 0.318
202209 0.169 125.227 0.178
202212 0.345 125.222 0.363
202303 0.357 127.348 0.369
202306 0.419 128.729 0.429
202309 0.383 129.860 0.389
202312 0.253 129.419 0.258
202403 0.520 131.776 0.520

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (STU:1FG) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


FibroGen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (STU:1FG) Business Description

Industry
Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

FibroGen (STU:1FG) Headlines

No Headlines